Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

from http://www.avidrp.com/

Research Grants 12 show all


$200K
2005

$497K
2007

$1M
2008

$748.7K
2009

$6.4M
2015

Publications 2 show all

  • 2
    Amyloid beta-Peptides/metabolism
  • 2
    Brain/diagnostic imaging
  • 1
    Alzheimer Disease/diagnostic imaging
  • 1
    Aniline Compounds/analysis
  • 1
    Aniline Compounds/metabolism
  • 1
    Benzene/metabolism
  • 1
    Brain/pathology
  • 1
    Ethylene Glycols/analysis
  • 1
    Ethylene Glycols/metabolism
  • 1
    Plaque, Amyloid/diagnostic imaging

Patents 114show all

  • 33
    A61K - Preparations for medical, dental, or toilet purposes
  • 18
    C07K - Peptides
  • 9
    A61B - Diagnosis
  • 7
    B82Y - Specific uses or applications of nanostructures
  • 7
    C07B - General methods of organic chemistry
  • 3
    C07C - Acyclic or carbocyclic compounds
  • 2
    G06K - Recognition of data
  • 1
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 1
    C07D - Heterocyclic compounds
  • 1
    Y02A - Technologies for adaptation to climate change

Clinical Trials 91show all

24Phase 220Phase 317Phase 110N/A6Phase 45Phase 2/Phase 34Other

SEC Filings show all


2
D

Contact Information

3711 Market Street 7th Floor
Philadelphia, PA 19104
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$69,900,00051-1002009-05-21Acquired

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2006-01-05$8,900,000Series AOUP (Osage University Partners), Pfizer Venture Investments, RK Ventures Group, Lilly Ventures, BioAdvance
2005-08-05Series ABioAdvance
2007-05-09$26,000,000Series CAllianceBernstein, Safeguard ScientificsBioAdvance, Lilly Ventures, RK Ventures Group, Pfizer Venture Investments
2009-05-21$34,500,000Series DAlta PartnersOUP (Osage University Partners), Safeguard Scientifics, Pfizer Venture Investments, RK Ventures Group, BioAdvance, AllianceBernstein, Lilly Ventures
2005-01-25$500,000SeedBioAdvance

SEC Form D Funding Events

DateOfferedSoldType
2009-11-30$34,547,508$34,547,508Equity
2008-11-21Unknown Unknown Other (Paper Filing)

Key Executives

  • Daniel M. Skovronsky
    Executive Officer, Director
  • Alan P. Carpenter
    Executive Officer
  • Richard A. Baron
    Executive Officer
  • William Hamilton
    Director
  • Gary J. Kurtzman
    Director
  • Ernest Mario
    Director
  • Matthew P. Rhodes-Kropf
    Director
  • Edward M. Hurwitz
    Director